New options for helicobacter pylori antibiotic treatment;Neue Möglichkeiten der Helicobacter-pylori-Behandlung mit Antibiotika

Deutsche Medizinische Wochenschrift

Volumn 136, Issue 28-29, 2011, Pages 1479-1484

  Misselwitz, Benjamin ^a   Kaiser, P ^a   Bauerfeind, P ^a   Vavricka, S R ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

Author keywords

antibiotic resistance; bacterial persistence; concomitant therapy; eradication; helicobacter pylori; sequential therapy; tailored therapy; triple therapy

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; HELICOBACTER INFECTION; HELICOBACTER PYLORI;

EID: 79960093248     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1281539     Document Type: Article

References (43)

1. Resinet-Studie. In: Nationales Referenzzentrum Helicobacter, Universität Freiburg; 2009
2. Atherton J C., Blaser M J. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009 119 2475-2487
3. Chang W L., Sheu B S., Cheng H C. et al,. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009 24 1230-1235
4. Chey W D., Wong B C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 1808-1825 (Pubitemid 47206706)
5. Falush D, Wirth T, Linz B et al,. Traces of human migrations in Helicobacter pylori populations. Science 2003 299 1582-1585 (Pubitemid 36297709)
6. Fischbach L, Evans E L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007 26 343-357 (Pubitemid 47063149)
7. Fischbach W, Malfertheiner P, Hoffmann J C. et al,. S3-guideline helicobacter pylori and gastroduodenal ulcer disease of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e.V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009 47 1230-1263
8. Fock K M., Ang T L., Bee L C., Lee E J. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008 47 1-6 (Pubitemid 350260884)
9. Fock K M., Katelaris P, Sugano K et al,. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009 24 1587-1600
10. Fock K M., Talley N, Moayyedi P et al,. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008 23 351-365 (Pubitemid 351342074)
11. Ford A C., Malfertheiner P, Giguere M et al,. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008 14 7361-7370
12. Fuccio L, Minardi M E., Zagari R M. et al,. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007 147 553-562 (Pubitemid 351664506)
13. Furuta T, Shirai N, Kodaira M et al,. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007 81 521-528 (Pubitemid 46452299)
14. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009 104 3069-3079; quiz 1080
15. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen L P. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001 20 820-823 (Pubitemid 34020461)
16. Graham D Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010 59 1143-1153
17. Graham D Y., Lew G M., Malaty H M. et al,. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992 102 493-496
18. Graham D Y., Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 2008 68 725-736 (Pubitemid 351550527)
19. Hsu P I., Wu D C., Wu J Y., Graham D Y. Modified Sequential Helicobacter pylori Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 Days. Helicobacter 2011 16 139-145
20. Ishizaki T, Sohn D R., Kobayashi K et al,. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994 16 214-215 (Pubitemid 24096631)
21. Kaakoush N O., Asencio C, Megraud F, Mendz G L. A redox basis for metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother 2009 53 1884-1891
22. Lambert J R., Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997 11 Suppl 1 27-33
23. Lee B H., Kim N, Hwang T J. et al,. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010 15 38-45
24. Lee M, Kemp J A., Canning A et al,. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999 159 2312-2316 (Pubitemid 29501531)
25. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007 5 48-56 (Pubitemid 44942303)
26. Linz B, Balloux F, Moodley Y et al,. An African origin for the intimate association between humans and Helicobacter pylori. Nature 2007 445 915-918
27. Luther J, Higgins P D., Schoenfeld P S. et al,. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010 105 65-73
28. Maggi-Solca N, Valsangiacomo C, Piffaretti J C. Prevalence of Helicobacter pylori resistant strains in the southern part of Switzerland. Clin Microbiol Infect 2000 6 38-40 (Pubitemid 36267462)
29. Malfertheiner P, Bazzoli F, Delchier J C. et al,. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011 377 905-913
30. Malfertheiner P, Megraud F, OMorain C et al,. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 772-781 (Pubitemid 46854190)
31. McColl K E. Helicobacter pylori and oesophageal cancer not always protective. Gut 2007 56 457-459 (Pubitemid 46580495)
32. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004 53 1374-1384 (Pubitemid 39120130)
33. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007 20 280-322 (Pubitemid 46709306)
34. Moayyedi P, Soo S, Deeks J et al,. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006 CD002096
35. Romano M, Cuomo A, Gravina A G. et al,. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010 59 1465-1470
36. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998 43 Suppl 1 S56-60 (Pubitemid 28338114)
37. Suzuki T, Matsuo K, Ito H et al,. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006 119 217-224 (Pubitemid 43255059)
38. Talley N J., Fock K M., Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008 103 510-514
39. Wang L H., Cheng H, Hu F L., Li J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 2010 16 2272-2277
40. Wu D C., Hsu P I., Wu J Y. et al,. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010 8 36-41 e31
41. Yuan Y, Ford A C., Khan K J., Moayyedi P. What Is the Optimum Duration of Proton Pump Inhibitor (PPI)-Based Triple Therapy for Helicobacter pylori ? 7,10, or 14 Days? Chicago DDW 2009
42. Yuen B, Zbinden R, Fried M, Bauerfeind P, Bernardi M. Cultural recovery and determination of antimicrobial susceptibility in Helicobacter pylori by using commercial transport and isolation media. Infection 2005 33 77-81 (Pubitemid 40590996)
43. Zhao F, Wang J, Yang Y et al,. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 2008 13 532-541